Clinical Trial Update: Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study of odronextamab in CD20+ B-cell malignancies completed; the trial reported safety and tolerability data in diseases including non-Hodgkin lymphoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Odronextamab (odronextamab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Status: COMPLETED